197 related articles for article (PubMed ID: 38020299)
1. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
[TBL] [Abstract][Full Text] [Related]
2. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.
Fan Y; Li Q; Shen Q; Liu Z; Zhang Z; Hu S; Yu W; He Z; He Q; Zhang Q
Front Oncol; 2022; 12():858865. PubMed ID: 35515131
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
4. Trop-2 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Nakano K; Kuwahara K; Minami T; Kato T; Hatano K; Kawashima A; Uemura M; Takao T; Fushimi H; Katayama K; Imoto S; Yoshimura K; Imamura R; Uemura H; Nonomura N
Curr Oncol; 2022 May; 29(6):3911-3921. PubMed ID: 35735421
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
6. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
7. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
8. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Perrone E; Lopez S; Zeybek B; Bellone S; Bonazzoli E; Pelligra S; Zammataro L; Manzano A; Manara P; Bianchi A; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Front Oncol; 2020; 10():118. PubMed ID: 32117765
[No Abstract] [Full Text] [Related]
10. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
12. Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target.
Wolber P; Nachtsheim L; Hoffmann F; Klußmann JP; Meyer M; von Eggeling F; Guntinas-Lichius O; Quaas A; Arolt C
Head Neck Pathol; 2021 Dec; 15(4):1147-1155. PubMed ID: 33886073
[TBL] [Abstract][Full Text] [Related]
13. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
16. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
Goldenberg DM; Stein R; Sharkey RM
Oncotarget; 2018 Jun; 9(48):28989-29006. PubMed ID: 29989029
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Mathew Thomas V; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.
Fontes MS; Vargas Pivato de Almeida D; Cavalin C; Tagawa ST
Onco Targets Ther; 2022; 15():1531-1542. PubMed ID: 36575731
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
20. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
